Roche Holding AG (RHHBY) said on Tuesday that the European Commission has approved Gazyva/Gazyvaro, in combination with mycophenolate mofetil (MMF), for the treatment of adult patients with active lupus nephritis.
The approval is based on positive results from the phase II NOBILITY and phase III REGENCY studies.
Gazyva/Gazyvaro is already approved for adults with lupus nephritis in the United States and is used in more than 100 countries to treat different types of blood cancers.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.